What is VRAX's relative strength rating?

VRAX ranks at the 41th percentile over 1 month, 5th percentile over 3 months, 12th percentile over 6 months, 6th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is VRAX in?

VRAX is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is VRAX in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). VRAX benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is VRAX?

VRAX currently shows a 20-day average daily range (ADR%) of 10.0%, a 90-day beta versus the S&P 500 of 0.42. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does VRAX have a seasonal pattern?

TickerStance computes VRAX's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what VRAX has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did VRAX last report earnings?

No SEC EDGAR filings are linked to VRAX in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Virax Biolabs Group Limited Ordinary Shares (VRAX)

TODAY'S READ · AS OF 2026-08-21

As of 2026-08-21, Virax Biolabs Group Limited Ordinary Shares (VRAX) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 29. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 10.0%, relative volume 0.12×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month5pctile

6 month12pctile

1 year6pctile

Classic5IBD pctile

LDR3leadership

0 of 5 lenses lit · avg RS pctile 6

✓ADR%10.0%✓A/DA!RVOL0.12×✓$ Vol$12M

COMPUTED · AS OF 2026-08-21

Pattern read

VRAX is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -6.6% / -46.9%.

Pure factual computation. Not a recommendation. See stage analysis.

Market backdrop

49.9Neutral

Trend30% weight46.6 Breadth30% weight58.1 Leadership20% weight36.3 Macro20% weight56.5 Full stance breakdown →

Evidence · 1 of 3

Receipts behind the read

0 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

41

3m

5

6m

12

1y

6

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

A/D ratingaccumulation / distribution

AAccum

RVOL todayvs 50d avg

0.12×

U/D ratiolast 50 sessions

14.37

Breakout volbreakout day vs 50d avg

-95%

50d avg $ volumeliquidity proxy

$12.0M

Risk profile

How much does it move?

Daily range, ATR, beta, and the math for a 1-ADR stop.

ADR% (20d)avg daily range

10.0%Elevated

ATR(14)14-day EMA

$0.46

ATR%ATR as % of close

14.43%

Beta vs SPY90d rolling

0.42

1-ADR stoprisk from close $3.19

$2.87−10.0%

Fundamentals · VRAX

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
VRAX
5RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Materials73

Industrials64

Financials55

Real Estate45

Consumer Staples36

RS pctileLagLead

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

IBIOiBio, Inc. Common Stock12 LCTXLineage Cell Therapeutics, Inc.12 COLLCollegium Pharmaceutical, Inc. Common Stock12 CELUCelularity Inc. Class A Common Stock12

§ Seasonality

10y · since 2022

Best monthAug on averageavg +51.09% · 25% win · n 4

Worst monthApr on averageavg -26.29% · 0% win · n 4

VRAX monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	VRAX Jan avg: -20.76% median: -21.52% win: 25% σ: 19.67% n: 4 2022-07-22 → 2026-07-31	VRAX Feb avg: -3.38% median: -5.68% win: 25% σ: 15.74% n: 4 2022-07-22 → 2026-07-31	VRAX Mar avg: -14.64% median: -14.47% win: 25% σ: 16.51% n: 4 2022-07-22 → 2026-07-31	VRAX Apr avg: -26.29% median: -26.56% win: 0% σ: 15.28% n: 4 2022-07-22 → 2026-07-31	VRAX May avg: 30.11% median: 19.71% win: 50% σ: 43.73% n: 4 2022-07-22 → 2026-07-31	VRAX Jun avg: -14.43% median: -9.72% win: 0% σ: 17.46% n: 4 2022-07-22 → 2026-07-31	VRAX Jul avg: -13.97% median: 1.72% win: 60% σ: 32.21% n: 5 2022-07-22 → 2026-07-31	VRAX Aug avg: 51.09% median: -17.48% win: 25% σ: 149.17% n: 4 2022-07-22 → 2026-07-31 (current)	VRAX Sep avg: -19.37% median: -9.74% win: 25% σ: 26.44% n: 4 2022-07-22 → 2026-07-31	VRAX Oct avg: -19.37% median: -16.05% win: 25% σ: 25.26% n: 4 2022-07-22 → 2026-07-31	VRAX Nov avg: -8.69% median: -5.03% win: 25% σ: 13.74% n: 4 2022-07-22 → 2026-07-31	VRAX Dec avg: -22.61% median: -25.66% win: 25% σ: 29.36% n: 4 2022-07-22 → 2026-07-31

Public attention · VRAX

Is the crowd watching?

51/ 100 · vs its own 90-day norm▲ 16 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2835

Float7.0Mshares

Shares out797Kshares

Market cap$2.5MNano Cap

FAQ

Frequently asked questions

What is VRAX's relative strength rating?: VRAX ranks at the 41th percentile over 1 month, 5th percentile over 3 months, 12th percentile over 6 months, 6th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is VRAX in?: VRAX is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is VRAX in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). VRAX benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is VRAX?: VRAX currently shows a 20-day average daily range (ADR%) of 10.0%, a 90-day beta versus the S&P 500 of 0.42. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does VRAX have a seasonal pattern?: TickerStance computes VRAX's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what VRAX has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
When did VRAX last report earnings?: No SEC EDGAR filings are linked to VRAX in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Virax Biolabs Group Limited Ordinary Shares (VRAX) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Virax Biolabs Group Limited Ordinary Shares (VRAX) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

§ Seasonality

Is the crowd watching?

Company snapshot

Frequently asked questions

§ Seasonality

Virax Biolabs Group Limited Ordinary Shares (VRAX) — Stance & relative strength

VRAX is not confirmed as a leader. 5 is not yet a leadership-grade RS read, Market Stance is 49.9

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Virax Biolabs Group Limited Ordinary Shares (VRAX) — Stance & relative strength

VRAX is not confirmed as a leader. 5 is not yet a leadership-grade RS read, Market Stance is 49.9

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions